Search

Displaying results 4951 - 4960 of 10000 in total
  1. Drug

    Brilaroxazine

    go.drugbank.com/drugs/DB09226
    Investigational

    Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease … Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists
  2. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

  3. Drug

    Flunixin

    go.drugbank.com/drugs/DB11518
    ExperimentalVet approved

    Flunixin may be also referred to as _Banamine_, and other trade names. … Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian.

  4. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  5. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    FDA approved in June 10, 2011 under the name of ezogabine. … Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine.

  6. Drug

    Hyperforin

    go.drugbank.com/drugs/DB01892
    InvestigationalNutraceutical

    Hyperforin is a phytochemical generated by the plants of the Hypericum family. … One of the most important members of this family, due to its medical properties, is _Hypericum perforatum_, also known as St John's wort.

  7. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy.

  8. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.

  9. Drug

    JB991

    go.drugbank.com/drugs/DB05081
    Experimental

    In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin. … The drug exerts marked antiproliferative and pro-apoptotic effect in human keratinocytes and fibroblasts in vitro.

  10. Drug

    GS-441524

    go.drugbank.com/drugs/DB15686
    Investigational

    [A203057,A203057] GS-441524 continues to be studied in the treatment of Feline Infectious Peritonitis Virus, a coronavirus that only infects cats.[A198840] … GS-441524 is an adenosine nucleotide analog antiviral, similar to [remdesivir].[A203057,L13239] This molecule was patented in 2009.